Skip to main content

Branded

  • Nearly 7-in-10 adults take a prescription drug, study finds

    ROCHESTER, Minn. — A large majority of Americans are taking prescription drugs, according to a new study by the Mayo Clinic.

    The study, published online in the journal Mayo Clinic Proceedings, found that nearly 70% of Americans are taking at least one drug, and more than half are taking two. Most of the drugs are antibiotics, antidepressants and opioid painkillers. Researchers said the data, which came from the Rochester Epidemiology Project, would be valuable because it would give insight into prescribing practices.

  • Three new Takeda diabetes drugs become available

    DEERFIELD, Ill. — Three new drugs for Type 2 diabetes made by Takeda Pharmaceutical Co. have become available in pharmacies, the company said.

    The drug maker announced the availability of Nesina (alogliptin), Kazano (alogliptin; metformin hydrochloride) and Oseni (alogliptin; pioglitazone).

  • Target's Canadian stores offer allergy advice for summer

    MISSISSAUGA, Ontario — Target Corp. is reaching out to Canadian customers preparing to send their children to summer camp with information and resources about allergies.

    The mass merchandise retailer, which has lately made a major push into Canada with 48 stores around the country, said its pharmacists would be available to provide advice on allergies.

  • Avella joins limited-distribution network for orally administered cancer drug

    PHOENIX — Avella Specialty Pharmacy will be included in the limited-distribution network for a cancer drug made by Genentech, Avella said Tuesday.

    The specially pharmacy company said it would be included in the network to sell Tarceva (erlotinib), an orally administered drug used to treat non-small cell lung cancer and pancreatic cancer. Genentech will shift distribution of Tarceva to a select group of pharmacies starting July 1 to align its distribution with that of similar cancer drugs.

  • Teva to acquire MicroDose for up to $165 million

    JERUSALEM — Teva Pharmaceutical Industries will spend up to $165 million to buy a company developing a drug to prevent viral respiratory infections.

    Teva said it would acquire MicroDose Therapeutx for $40 million, plus up to $125 million in milestone payments and sales milestones and royalties from its lead product, MDT-637, an inhaled treatment for respiratory syncytial virus, or RSV.

  • Mylan hires NFL player, TV personality to promote EpiPen

    BASKING RIDGE, N.J. — A division of Mylan is hiring NFL player Adrian Peterson and celebrity nanny Jo Frost to promote an emergency treatment for severe allergic reactions.

    Mylan Specialty announced that it had hired the two — who both have potentially life-threatening allergies — to raise awareness of the problem. Mylan Specialty is launching a multichannel marketing campaign for the EpiPen (epinephrine) auto-injector to mark the 25th anniversary of its approval by the Food and Drug Administration.

  • Royalty Pharma drops bid for Elan Corp.

    NEW YORK — Royalty Pharma will not buy Irish drug maker Elan Corp., the company said Tuesday.

    Royalty said it would withdraw a request for a review by the Irish Takeover Panel after Elan shareholders voted in favor of a share buyback. Elan said last week that it would begin a process of selling itself to Royalty, which had previously offered $13 per share for the company.

  • J&J to buy Aragon Pharmaceuticals for up to $1 billion

    NEW BRUNSWICK, N.J. — Drug maker Johnson & Johnson plans to spend up to $1 billion to acquire a privately owned company developing a drug for prostate cancer.

    J&J said Monday it would acquire Aragon Pharmaceuticals for $650 million upfront plus up to $350 million in milestone payments, with the expectation that the deal will close in third quarter 2013.

X
This ad will auto-close in 10 seconds